Clinical Trial Update: Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the combination of gemcitabine, trastuzumab, and pertuzumab in patients with metastatic HER2-positive breast cancer after prior HER2-t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic HER2-Positive Breast Cancer | Phase 2 | Status: COMPLETED